PMC10098014_01
Timeline of the clinical course.
fsurg-10-1133335-g001.jpg
PMC10098014_01_fsurg-10-1133335-g001.jpg
F1
As shown in the clinical time line of Figure 1, a 48-year-old woman was admitted to the local hospital due to highly elevated serum AFP level during a yearly routine physical examination. After three courses of the combined therapy, the serum AFP level decreased from 748.5 to 12.9 ng/mL (Figure 1) and the tumor shrunk (Figure 3B).
Pathological findings (A) Endoscopic biopsy before chemo-immunotherapy at local hospital (Hematoxylin-eosin staining, magnification x10); (B) Tumor area and (C) lymph node after 3 courses of chemo-immunotherapy (Hematoxylin-eosin staining, magnification x10).
fsurg-10-1133335-g002.jpg
PMC10098014_01_fsurg-10-1133335-g002.jpg
F2
She underwent upper endoscopy and was found to have HAS in the cardia verified by pathological examination (Figure 2A). D2 radical gastrectomy was then performed and no residual tumor cells were found in resected tissue; most of the cells appeared to degenerate and die (Figures 2B,C).
Abdominal CT imaging (A) Before chemo-immunotherapy; (B) After 3 courses of chemo-immunotherapy.
fsurg-10-1133335-g003.jpg
PMC10098014_01_fsurg-10-1133335-g003.jpg
F3
III (Figure 3A). Immunohistochemistry (IHC) showed c-erbB-2(GC) 1+, c-ervB-2(GC)-Positive Control 3+, MSH2+, MSH6+, MLH1+, PMS2+, SALL4+, AFP+, After three courses of the combined therapy, the serum AFP level decreased from 748.5 to 12.9 ng/mL (Figure 1) and the tumor shrunk (Figure 3B).